Medicare beneficiaries who rely on Ozempic or Wegovy will pay no more than $274 a month for those drugs starting Jan. 1, 2027, after the Centers for Medicare and Medicaid Services locked in negotiated prices that cut costs by 71 percent. The agency set the maximum fair price as part of the second cycle of the Medicare Drug Price Negotiation Program, covering 15 drugs for cancer and chronic conditions. According to a recent CMS announcement, the lower price is expected to save seniors roughly $685 million, and a separate bridge program already running offers even steeper short-term discounts while the negotiated rate takes hold.
Why the $274 maximum fair price changes the math for seniors now
Before this agreement, many Part D enrollees faced monthly costs for semaglutide-based drugs that exceeded $900, depending on plan design and where they fell in the benefit phases. For some, coinsurance percentages applied to high list prices translated into four-figure pharmacy bills at the start of each year. The negotiated $274 ceiling represents the first time the federal government has directly set a price for GLP-1 medications under the Inflation Reduction Act’s negotiation authority. That distinction matters because it applies across all Part D plans, not just those that independently negotiated rebates with Novo Nordisk.
The new maximum fair price also simplifies planning for beneficiaries and caregivers. Instead of trying to decode formulary tiers, preferred pharmacy networks, and shifting coinsurance rates, patients can expect a uniform upper bound on what Medicare will recognize as the fair monthly charge for these drugs. Plans can still structure copays and utilization management, but they must do so within the constraint of the $274 negotiated figure, rather than starting from a much higher list price.
A parallel initiative adds another layer of relief in the near term. The Medicare GLP-1 Bridge program, which began July 1, 2026, and runs through Dec. 31, 2027, caps beneficiary access at $50 per month. Participating manufacturers supply eligible GLP-1 drugs at a net price of $245 per monthly supply under that demonstration. So for the second half of 2027, two price tracks will overlap: the $274 IRA-negotiated maximum fair price and the $245 Bridge net price, each flowing through different program rules.
The practical effect is that seniors who qualify for the Bridge pay less than the negotiated rate during the overlap window, while those outside the demonstration still benefit from the $274 cap. Either way, out-of-pocket exposure drops sharply compared with pre-negotiation levels. For lower-income beneficiaries who already receive Part D subsidies, the combination of capped prices and existing cost-sharing protections could make continuous use of GLP-1 therapies more feasible, reducing the likelihood that patients start and stop treatment because of affordability shocks.
Whether this price shift accelerates prescribing of Ozempic and Wegovy over older, cheaper diabetes agents is a question clinicians and actuaries are already tracking. Lower cost barriers could steer more Part D enrollees toward GLP-1 therapies that carry documented cardiovascular benefits, though measurable changes in hospitalization rates would take at least two years of claims data to confirm. Health systems may also revisit care management protocols, since more predictable access to these drugs allows for longer-term planning around weight loss, glycemic control, and complication prevention.
How CMS arrived at the $274 price for Ozempic and Wegovy
CMS published the negotiated prices for all 15 second-cycle drugs on its negotiated prices page, which includes a dedicated ZIP file containing the maximum fair price explanation for Ozempic, Rybelsus, and Wegovy for initial price applicability year 2027. That file details the agency’s rationale, therapeutic comparisons, and the offer-and-counteroffer process that produced the final figure, including how CMS weighed evidence on clinical outcomes and utilization patterns in the Medicare population.
Earlier in the process, the Department of Health and Human Services issued final guidance for the second negotiation cycle, clarifying what CMS could consider during talks: clinical benefit relative to existing options, the drug’s impact on Medicare spending, availability of therapeutic alternatives, and manufacturer-specific factors such as research and development costs and federal support. Within that framework, CMS evaluated semaglutide’s role in treating type 2 diabetes and obesity, as well as its cardiovascular risk-reduction data in high-risk patients.
For GLP-1 drugs, those clinical considerations are central. Semaglutide-based therapies have demonstrated not only improved glycemic control and weight loss, but also reductions in major adverse cardiovascular events in certain populations. CMS weighed those outcomes against the presence of older, lower-cost diabetes medications, some of which lack comparable evidence on cardiovascular endpoints. The agency’s explanation document indicates that these comparative benefits supported a maximum fair price above generic alternatives but well below the existing list price.
The negotiated outcome reflects a balance between rewarding innovation and protecting program sustainability. By anchoring the Medicare price at $274, CMS aims to ensure broad access while signaling that future high-cost drugs will be subject to similar scrutiny under the Inflation Reduction Act. Manufacturers retain the ability to set prices in the commercial market, but Medicare’s purchasing power now exerts a clearer downward pull on what seniors pay at the pharmacy counter.
For beneficiaries and clinicians, the details of the negotiation may be less visible than the bottom line: a predictable, substantially lower monthly cost for Ozempic and Wegovy, reinforced by a temporary bridge program that drives out-of-pocket charges even lower for many users. As these policies roll out, the key metrics to watch will be adherence rates, shifts in prescribing toward GLP-1 therapies, and downstream trends in diabetes complications and cardiovascular events among Medicare enrollees.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
